Additionally, our data show novel applications of the spindle-inhibitor ispinesib and we found an efficacious combination between ispinesib and cabozantinib, which could be a valuable option for patients with resistant FLT3-ITD+ AML, failing to respond to targeted FLT3 inhibitors. The gene discussed is FLT3; the disease is acute myeloid leukemia.